{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T20:03:47Z","timestamp":1751054627431},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the field of postmenopausal osteoporosis, the quality of bone has gained more attention than the quantity, so the most important part of anti-osteoporotic efficacy of an agent translates its capacity to reduce osteoporotic fractures. Ten years' experience with alendronate has a lot of conflicting data that have to be discussed in detail. Health care professionals in the field of postmenopausal osteoporosis question the antifracture efficacy of a drug more quickly than its favorable effects on BMD. The aim of this paper is to present the complexity of the results in this 10-year trial that has caused difficulty in its interpretation. Ten-year data of alendronate resulted in inconclusive evidence because of the small sample size, high drop-out rate, heterogeneous distribution of subjects in each arm of the trial, and biologically unexplainable results of the fracture rates. The need for further well-designed trials on long-term antifracture efficacy of antiosteoporotic drugs still remains.<\/jats:p>","DOI":"10.1359\/jbmr.050504","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T09:06:25Z","timestamp":1146128785000},"page":"1480-1481","source":"Crossref","is-referenced-by-count":2,"title":["Are We Treating Women With Postmenopausal Osteoporosis for Their Low BMD or High Fracture Risk?"],"prefix":"10.1093","volume":"20","author":[{"given":"Murat","family":"Api","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Education and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019250800600_bib1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019250800600_bib2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50\u201364 and 65 and older: Results from the National Osteoporosis Risk Assessment (NORA)","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019250800600_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1359\/jbmr.2001.16.5.799","article-title":"Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral density can seriously mislead diagnostic\/prognostic interpretations of patient-specific bone fragility","volume":"16","author":"Bolotin","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019250800600_bib4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1532-5415.2004.52420.x","article-title":"Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis","volume":"52","author":"Silverman","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"2024013019250800600_bib5","first-page":"1437","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/8\/1480\/56478123\/5650200820.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/8\/1480\/56478123\/5650200820.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:09:28Z","timestamp":1710342568000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/8\/1480-1481\/7593134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":5,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050504","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8,1]]},"published":{"date-parts":[[2005,8,1]]}}}